Avalyn Pharma Inc. AVLN
Set alert
26.30 USD +0.70 +2.75%
As of Nov 3, 2:34 PM ET
25.45 Day range 26.82
22.24 52-week range 40.17
- YTD
- -10.81%
- 1 year
- -10.81%
- Open
- 25.87
- Prev close
- 25.60
- Mkt cap
- 1.17B
- Vol
- 295.00K
- Avg vol
- 289.84K
- EPS
- -2.47
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.45
- High
- 26.82
- Forward P/E
- -9.92
- Beta
- 0.00
- Short ratio
- 7.21
- Inst. own
- 104.07%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 30.16
- 200-d avg
- 29.99
- 1y target
- 61.80
3M chart
Events in this range
- Aug 12, 2026Earnings: -0.98; estimate -0.77667; surprise -26.18%
- Aug 13, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 2, 2026Rating: Raymond James · — → Outperform
Signals (11)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 2026 | 5 hours ago |
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 61.80 +135.0% upside
Now 26.30
- Target (low)
- 52.00
- Target (mean)
- 61.80
- Target (high)
- 80.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.75 | -0.79 – -0.71 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next quarter | -0.72 | -0.72 – -0.72 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Current year | -2.69 | -2.69 – -2.69 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Next year | -2.58 | -2.58 – -2.58 | -2.69 | +4.1% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Raymond James | Initiated | — | Outperform |
| Aug 13, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 26, 2026 | Evercore ISI Group | Initiated | — | Outperform |
| May 26, 2026 | Guggenheim | Initiated | — | Buy |
| May 26, 2026 | Morgan Stanley | Initiated | — | Overweight |